Adrienne G. Waks, MD, physician, associate director, Breast Oncology Clinical Research, Dana-Farber Cancer Institute, assistant professor, medicine, Harvard Medical School, discusses how the efficacy and safety profiles of anthracycline- and taxane-based regimens compare with one another as neoadjuvant and adjuvant treatment options for patients with HER2-positive breast cancer.
Website: [ Ссылка ]
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
LinkedIn: [ Ссылка ]
